Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) announced today that two SNS01-T abstracts have been accepted for presentation at the 54 th American Society of Hematology (ASH) Annual Meeting and Exposition to be held on December 8-11 in Atlanta, Georgia. The abstracts are available on the ASH website at www.hematology.org. “We are pleased that Dr. Lust, the PI at Mayo, will be providing an interim update on the encouraging results from the Phase 1b/2a trial,” stated Dr. Leslie J. Browne, President & CEO of Senesco. Dr. Browne continued, “Also there will be an opportunity for a detailed discussion of the striking results of combining SNS01-T with lenalidomide, the active ingredient in REVLIMID ®, in animal models of multiple myeloma and mantle cell lymphoma. The poster will be attended by Catherine Taylor from Senesco CSO John Thompson’s research laboratory at the University of Waterloo.” Abstracts to Be Presented:
About Senesco Technologies, Inc. Senesco, a leader in eIF5A technology, is sponsoring a clinical study to evaluate its lead therapeutic candidate SNS01-T in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma. SNS01-T targets B-cell cancers and selectively induces apoptosis by modulating eukaryotic translation initiation factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology and biofuels development, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ commercialized products.
|1.||“Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma” – Abstract # 53188 Sunday, December 9, 2012, 6:00 PM-8:00 PM, Hall B1-B2, Level 1, Building B (Georgia World Congress Center)|
|John A Lust, MD, PhD 1, Saad Z Usmani, MD FACP 2, Mehdi Hamadani, MD 3, Charles Barranco 4*, Martha Q Lacy, MD 1, Angela Dispenzieri, MD 1, Morie A Gertz 1, David Dingli, M.D., Ph.D. 1, Stephen Russell, MD, PhD 1*, Francis K Buadi, M.D. 1, Steven R Zeldenrust, MD, PhD 1, Suzanne R Hayman, MD 1, S. Vincent Rajkumar, MD 1, Shaji K. Kumar, MD 1, John Thompson 5*, Catherine A Taylor 5* and Richard Dondero 6*|
|1Division of Hematology, Mayo Clinic, Rochester, MN, 2Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 3Hematology/Oncology Bone Marrow Transplant, West Virginia University Hospitals, Inc., Morgantown, WV, 4Senesco Technologies, Inc., Bridgewater, NJ, 5Biology, University of Waterloo, Waterloo, ON, Canada, 6Senesco Technologies Inc., Bridgewater, NJ|
|2.||“Combination Therapy with Novel Nanoparticle, SNS01-T, and Lenalidomide Triggers Synergistic Cytotoxicity in Vitro and in Vivo in Multiple Myeloma and Mantle Cell Lymphoma” – Abstract # 51240 Monday, December 10, 2012, 6:00 PM-8:00 PM, Hall B1-B2, Level 1, Building B (Georgia World Congress Center)|
|Catherine A Taylor 1, Terence Tang 1, Zhongda Liu 1, Sarah Francis 1, Zheng Qifa 1, Richard Dondero 2 and John Thompson 1,2|
|1Biology, University of Waterloo, Waterloo, ON, Canada 2Senesco Technologies Inc., Bridgewater, NJ|
Forward-Looking StatementsCertain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company’s ability to continue as a going concern; the Company’s ability to recruit patients for its clinical trial; the ability of the Company to consummate additional financings; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance, the quotation of the Company’s common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"), as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.